UNITY 1: A STUDY OF AN INVESTIGATIONAL TREATMENT REGIMEN OF DACLATASVIR (DCV) + ASUNAPREVIR (ASV) + BMS-791325 IN A FIXED DOSE COMBINATION (THE DCV 3DAA (DIRECT ACTING ANTIVIRAL) REGIMEN) FOR 12 WEEKS FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION IN NON-CIRRHOTIC SUBJECTS: